Business Context and Reporting Period
This Form 8-K filing by Quince Therapeutics, Inc. (QNCX) reports on events occurring on December 29, 2023. The company is a Delaware corporation with its principal executive offices in South San Francisco, California, and its common stock trades on The Nasdaq Global Select Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance regarding stock listing requirements rather than financial performance.
Material Changes
The primary material event reported is the resolution of a Nasdaq listing deficiency:
- Previous Status: On December 4, 2023, the company received notice that its common stock closing bid price had been below $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1).
- Resolution: On December 29, 2023, Nasdaq notified the company that the closing bid price had been $1.00 per share or greater for the 13 consecutive business days ending December 28, 2023.
- Outcome: The company has regained compliance with the minimum bid price requirement, and the matter is now closed.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. The primary risk addressed was the potential delisting due to low stock price, which has been mitigated by the recent price recovery. No other contingencies or unusual items are disclosed in this document.
Investor Verification Checklist
- Verify the current trading price of QNCX to ensure continued compliance with the $1.00 minimum bid price requirement.
- Review the company's most recent 10-K or 10-Q filings for actual financial performance data, as this 8-K contains none.
- Monitor future Nasdaq communications to confirm no new compliance issues arise.